European Medicines Agency starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373)

Decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults which suggest that the vaccine triggers production of antibodies and immune cells that target SARS-CoV-2.

Source:

European Medicines Agency